Uncategorized

As populations age, hospital capacity overflows and the data-driven digital age rapidly expands, diagnostics are the low-cost/high-value levers that can reduce pressure on the parts of our system that are hardest to scale – hospital beds, specialist time, complex procedures, and emergency care.  Watch Dr Mark O’Brien’s 2-minute video overview for a sneak peek at

PTA Presents to 300 Health Supply and Procurement Officers    PTA CEO, Dean Whiting, gave a plenary presentation at the 36th annual Association of Health Supply and Procurement Officers (AHSPO) conference in Lorne, Victoria.   Starting with a brief survey of the audience which indicated that about 1 quarter of the room were involved in pathology

    PTA is so proud of one of our newest members Ketim Technologies and Clarissa Yates, PhD, for winning the LX Health Accelerator Startup of the Year Award. Amongst the many brilliant innovations that Australian IVD start-ups are developing, a test that identifies mums at risk of developing postpartum depression is such an important

Congratulations to our members, Roche Diagnostics, showcasing an excellent example of pathology technology empowering transformational change: early detection of Alzheimer’s can significantly impact the trajectory of patients, their loved ones, and our whole society. There are many stories like this one, where information from simple tests support the best care for patients. It’s important to

Our engagement in the Medical Device Single Audit Program (MDSAP) journey, on behalf of members, has taken us the different parts of the world, over the past year or so. Even if it is mostly via very late night online calls. It’s important to make sure our members’ voice is heard and that the single audit program

New PTA-C/26 Report Highlights the Path Forward for Australia’s Healthcare System What will it take to create a more sustainable, preventative and patient-centred healthcare system? The insights from Pathology Technology Australia’s PTA-C/26 Congress point to a clear answer: greater investment in diagnostics, stronger collaboration across the health sector, and policy reform to unlock innovation. Bringing

Healthcare Affordability Must Be Paired with Investment in Diagnostic Infrastructure – PTA’s response to the 2026 Federal Health Budget   “Diagnostics inform 70% of medical decisions. Without investment in the pathology services, technology, and infrastructure that enable accurate, timely diagnosis, we risk creating a bottleneck where patients can afford to see their GP but can’t

Genomics Australia Update  PTA participates in regular discussion and updates with Genomics Australia Commissioner Tiffany Boughtwood, and Director Renaye Lucchese.   Here is an update of the current state:  Genomics Australia is setting the vision for health genomics in Australia for the next 10 years. By 2035 Genomics Australia foresees genomics transforming healthcare to focus on

New Licensing Agreement Supports a Maturing Clinical Genomics Infrastructure Landscape. A recently announced licensing agreement between Genomical and Illumina – two PTA members – signals support for the broader shift in how clinical genomic laboratories are approaching workflow integration and data management. For accredited clinical laboratories, timely rollout of new genomic tests can be supported through

New National Framework for Chronic Diseases  11 March 2026  Health Minster Mark Butler announces an investment of $110 million over three years on projects that help prevent chronic conditions. This funding forms part of the newly launched National Strategy Framework for Chronic Conditions 2026-35 (NSFCC).  Over half of all Australian have at least one chronic condition and about 24% have